Affinage

PNPLA1

Omega-hydroxyceramide transacylase · UniProt Q8N8W4

Length
532 aa
Mass
57.9 kDa
Annotated
2026-06-10
28 papers in source corpus 11 papers cited in narrative 11 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PNPLA1 is a CoA-independent transacylase expressed specifically in differentiated keratinocytes that catalyzes the final, committed step of ω-O-acylceramide biosynthesis required to build the epidermal permeability barrier (PMID:28248318, PMID:28248300, PMID:28369476). Working with purified recombinant enzyme, PNPLA1 transfers fatty acid from triglyceride donors (trilinolein and dilinolein) onto ω-hydroxyceramide, ω-hydroxyglucosylceramide, and ω-hydroxy acid acceptors, generating acylceramide, glucosyl-acylceramide, and acyl acid; it selects linoleate over oleate with ~3:1 preference, accounting for the linoleic acid enrichment of epidermal acylceramides, and also esterifies γ-linolenic acid onto ceramide 1 (PMID:37087101, PMID:38340658). In keratinocyte-specific and global Pnpla1 knockout mice, acylceramides and their O-acyl-ω-hydroxy fatty acid components are nearly absent while precursors accumulate, producing a disorganized extracellular lipid matrix, defective lipid coverage of the cornified envelope, and neonatal lethality from barrier failure (PMID:28248300, PMID:28369476). PNPLA1 acquires its triglyceride substrate at cytosolic lipid droplets, to which it is recruited by the coactivator ABHD5 (CGI-58); spatial co-localization of the two proteins at the droplet — rather than obligate direct binding — is sufficient to activate PNPLA1, as shown by proteoliposome reconstitution, and ABHD5 disease mutations abolish activation by impairing either PNPLA1 recruitment or ABHD5's own droplet association (PMID:30361410, PMID:30527376, PMID:40818613). Loss-of-function mutations in the catalytic domain of PNPLA1 cause autosomal recessive congenital ichthyosis, with the great majority of patient missense variants completely abolishing acylceramide-producing activity (PMID:22246504, PMID:35970721).

Mechanistic history

Synthesis pass · year-by-year structured walk · 8 steps
  1. 2012 High

    Established PNPLA1 as a gene essential for the epidermal lipid barrier, answering whether it has a non-redundant role in skin physiology.

    Evidence GWAS in dogs and Sanger sequencing of human ARCI patients with histological follow-up

    PMID:22246504

    Open questions at the time
    • Did not define the biochemical reaction catalyzed
    • No substrate or product identified
    • Subcellular site of action unknown
  2. 2017 High

    Defined PNPLA1's molecular function as the transacylase catalyzing the final ω-O-esterification step of acylceramide synthesis, linking enzyme activity directly to disease mutations.

    Evidence Cell-based and in vitro transacylase assays with recombinant PNPLA1 plus active-site mutagenesis of patient variants, confirmed by KO mouse lipidomics and electron microscopy of lipid lamellae

    PMID:28248300 PMID:28248318 PMID:28369476

    Open questions at the time
    • Source and presentation of the triglyceride substrate not yet defined
    • Acceptor substrate range incompletely mapped
    • Fatty acid selectivity not quantified
  3. 2018 High

    Identified ABHD5 (CGI-58) as the coactivator that recruits PNPLA1 to lipid droplets, answering how the enzyme accesses its triglyceride substrate.

    Evidence Co-immunoprecipitation, cell-based acylceramide assays, and immunofluorescence/immunoelectron microscopy in co-expression systems

    PMID:30361410 PMID:30527376

    Open questions at the time
    • Whether direct binding or spatial proximity drives activation not resolved
    • Mechanism of triglyceride presentation inferred from imaging only
  4. 2018 Medium

    Proposed an additional role for PNPLA1 in lipophagy-mediated lipid droplet turnover, raising the question of whether barrier defects involve autophagy.

    Evidence BODIPY staining, immunoblotting, and siRNA knockdown in ARCI patient and control fibroblasts

    PMID:30655104

    Open questions at the time
    • Mechanism not reconstituted; autophagy link is correlative
    • Relationship to transacylase activity unclear
    • Observed in fibroblasts rather than keratinocytes
  5. 2022 High

    Systematically tied PNPLA1 patient variants to loss of catalytic activity and showed lipid droplet localization is necessary but not sufficient for activity.

    Evidence Cell-based acylceramide assay and immunofluorescence across sixteen ichthyosis-associated missense mutations

    PMID:35970721

    Open questions at the time
    • Single-lab dataset
    • Structural basis for activity loss not determined
    • Why some inactive mutants still localize to droplets unexplained
  6. 2023 High

    Reconstituted PNPLA1 transacylase activity with purified enzyme and defined substrates, quantifying its ~3:1 linoleate-over-oleate selectivity and broad acceptor range.

    Evidence In vitro assays with E. coli-expressed truncated recombinant PNPLA1, liposomal substrates, and HPLC-UV/LC-MS product analysis

    PMID:37087101

    Open questions at the time
    • Used truncated enzyme rather than full-length
    • Structural determinants of fatty acid selectivity not defined
    • Role of ABHD5 in the purified system not tested here
  7. 2024 Medium

    Extended PNPLA1's acceptor/donor scope to γ-linolenic acid esterification of ceramide 1 in human keratinocytes, broadening its substrate repertoire beyond linoleic acid.

    Evidence siRNA knockdown in differentiated normal human keratinocytes with LC-MS lipidomic quantification of ceramide subspecies

    PMID:38340658

    Open questions at the time
    • Single-lab knockdown study
    • Relative physiological contribution of GLA vs LA esterification unquantified
  8. 2025 High

    Resolved the mechanism of ABHD5 activation, showing spatial proximity rather than direct binding is sufficient to activate PNPLA1 and dissecting two distinct mutational failure modes.

    Evidence Cell-based assays and immunofluorescence of seven ABHD5 missense mutations plus proteoliposome reconstitution rescuing PNPLA1 activity by restoring co-localization

    PMID:40818613

    Open questions at the time
    • Molecular details of substrate hand-off at the droplet surface remain undefined
    • Role of perilipins in droplet targeting inferred, not directly tested

Open questions

Synthesis pass · forward-looking unresolved questions
  • A high-resolution structural model of PNPLA1, its catalytic mechanism, and the geometry of triglyceride/ceramide substrate engagement at the lipid droplet interface remain to be established.
  • No experimental structure of PNPLA1
  • Structural basis of linoleate selectivity unknown
  • How autophagy/lipophagy role integrates with transacylase function unresolved

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 4 GO:0016787 hydrolase activity 2
Localization
GO:0005811 lipid droplet 3 GO:0005829 cytosol 2
Pathway
R-HSA-1266738 Developmental Biology 3 R-HSA-1430728 Metabolism 3
Partners
ABHD5

Evidence

Reading pass · 11 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2012 PNPLA1 mutations (including a premature stop codon in dogs, and missense/nonsense mutations in the catalytic domain in humans) cause autosomal recessive congenital ichthyosis, establishing PNPLA1 as essential for epidermal lipid barrier formation. Genome-wide association study in dogs, Sanger sequencing in human patients, histological and localization experiments Nature genetics High 22246504
2017 PNPLA1 is a transacylase that catalyzes the final step of ω-O-acylceramide synthesis by esterifying ω-hydroxyceramide with linoleic acid derived from triglyceride; ichthyosis-associated mutant forms of PNPLA1 show reduced or absent transacylase activity in cell-based and in vitro assays. Cell-based acylceramide production assays, in vitro enzyme assays with recombinant PNPLA1, active-site mutagenesis analysis of patient-derived variants Nature communications High 28248300 28248318
2017 Keratinocyte-specific or global Pnpla1 knockout in mice causes neonatal lethality due to severe epidermal permeability barrier defects, with near-complete absence of acylceramides, acylglucosylceramides, and O-acyl-ω-hydroxy fatty acids in epidermis and reciprocal accumulation of their precursors, confirming PNPLA1 catalyzes ω-O-esterification with linoleic acid in vivo. Keratinocyte-specific and global knockout mouse models, lipidomic analysis of stratum corneum, electron microscopy of intercellular lipid lamellae Nature communications High 28248300 28369476
2017 PNPLA1 is specifically expressed in differentiated keratinocytes; Pnpla1-deficient epidermis shows defective lipid coverage of the cornified envelope and disorganized extracellular lipid matrix, linking PNPLA1 enzymatic activity to cornified envelope formation. Knockout mouse analysis, immunohistochemistry, lipid mass spectrometry, analysis of patient stratum corneum Human molecular genetics High 28369476
2018 ABHD5 (CGI-58) acts as a coactivator of PNPLA1 by physically interacting with PNPLA1 and recruiting it to cytosolic lipid droplets where its triglyceride substrate resides, thereby stimulating PNPLA1-catalyzed acylceramide production; disease-associated ABHD5 missense mutations fail to enhance PNPLA1 activity. Co-immunoprecipitation, cell-based acylceramide production assay, indirect immunofluorescence microscopy, immunoelectron microscopy Journal of lipid research High 30361410 30527376
2018 ABHD5 co-expression causes PNPLA1 to localize on lipid droplet membranes or their periphery (rather than dispersed in the cytosol); under high co-expression, lipid droplets disappear and appear to transform into vesicles or become incorporated into the ER, suggesting ABHD5 presents triglyceride substrate to PNPLA1. Indirect immunofluorescence microscopy, immunoelectron microscopy in HeLa cells with co-expression system Journal of dermatological science Medium 30527376
2018 PNPLA1 mutations (p.Y245del and p.D172N) in ARCI patient fibroblasts cause abnormal intracellular lipid droplet accumulation associated with decreased LC3 expression and reduced autophagosome formation and autophagosome-lysosome fusion, indicating a role for PNPLA1 in lipophagy-mediated lipid droplet regulation. Fluorescence staining (BODIPY), immunocytochemistry, immunoblotting, siRNA knockdown of PNPLA1 in control fibroblasts Journal of dermatological science Medium 30655104
2022 Fifteen of sixteen tested ichthyosis-associated PNPLA1 missense mutations cause complete loss of acylceramide-producing activity in a cell-based assay; one mutation (C216R) only weakly reduces activity, correlating with milder patient symptoms. Mutants with no activity show variable intracellular localization: some localize to lipid droplets (S19L, D172N), others partially (eight mutants), and five remain cytosolic, indicating that lipid droplet localization is necessary but not sufficient for activity. Cell-based acylceramide production assay with co-overexpression, indirect immunofluorescence microscopy Journal of dermatological science High 35970721
2023 Recombinant truncated PNPLA1 (expressed in E. coli) catalyzes acyl transfer from trilinolein and dilinolein to ω-hydroxyceramide, ω-hydroxyglucosylceramide, and ω-hydroxy acid acceptors, forming acylceramide, glucosyl-acylceramide, and acyl acid respectively; PNPLA1 transfers linoleate with approximately 3:1 selectivity over oleate, explaining in vivo linoleic acid enrichment of acylceramides. In vitro enzyme assay with purified recombinant PNPLA1, liposomal substrates, HPLC-UV and LC-MS product analysis Journal of lipid research High 37087101
2024 siRNA-mediated knockdown of PNPLA1 in differentiated normal human keratinocytes reduces levels of both LA-esterified and GLA-esterified ceramide 1 subspecies and accumulates non-esterified ω-hydroxy ceramide precursors, demonstrating that PNPLA1 is responsible for esterification of γ-linolenic acid (GLA) as well as linoleic acid to ceramide 1. siRNA knockdown in differentiated normal human keratinocytes, LC-MS lipidomic quantification of ceramide subspecies Biochemical and biophysical research communications Medium 38340658
2025 ABHD5 disease-associated mutations disrupt PNPLA1 function by two distinct mechanisms: (i) mutations in the PNPLA1-binding region of ABHD5 impair PNPLA1 recruitment to lipid droplets; (ii) mutations in potential perilipin-binding domains prevent ABHD5 from associating with lipid droplets, indirectly disrupting PNPLA1 localization. Restoring co-localization of ABHD5 mutants with PNPLA1 in proteoliposomes rescues full PNPLA1 enzyme activity, indicating that spatial proximity (not direct binding) is sufficient for PNPLA1 activation. Analysis of seven ABHD5 missense mutations in cell-based assays, immunofluorescence microscopy, proteoliposome reconstitution assay Journal of lipid research High 40818613

Source papers

Stage 0 corpus · 28 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2012 PNPLA1 mutations cause autosomal recessive congenital ichthyosis in golden retriever dogs and humans. Nature genetics 198 22246504
2017 PNPLA1 has a crucial role in skin barrier function by directing acylceramide biosynthesis. Nature communications 111 28248300
2017 PNPLA1 is a transacylase essential for the generation of the skin barrier lipid ω-O-acylceramide. Nature communications 106 28248318
2018 Molecular mechanism of the ichthyosis pathology of Chanarin-Dorfman syndrome: Stimulation of PNPLA1-catalyzed ω-O-acylceramide production by ABHD5. Journal of dermatological science 47 30527376
2018 The role of PNPLA1 in ω-O-acylceramide synthesis and skin barrier function. Biochimica et biophysica acta. Molecular and cell biology of lipids 46 30290227
2018 ABHD5 stimulates PNPLA1-mediated ω-O-acylceramide biosynthesis essential for a functional skin permeability barrier. Journal of lipid research 46 30361410
2017 PNPLA1 defects in patients with autosomal recessive congenital ichthyosis and KO mice sustain PNPLA1 irreplaceable function in epidermal omega-O-acylceramide synthesis and skin permeability barrier. Human molecular genetics 44 28369476
2016 Gene-Targeted Next Generation Sequencing Identifies PNPLA1 Mutations in Patients with a Phenotypic Spectrum of Autosomal Recessive Congenital Ichthyosis: The Impact of Consanguinity. The Journal of investigative dermatology 31 27884779
2017 Sixteen novel mutations in PNPLA1 in patients with autosomal recessive congenital ichthyosis reveal the importance of an extended patatin domain in PNPLA1 that is essential for proper human skin barrier function. The British journal of dermatology 28 28093717
2018 Impairment of lipophagy by PNPLA1 mutations causes lipid droplet accumulation in primary fibroblasts of Autosomal Recessive Congenital Ichthyosis patients. Journal of dermatological science 12 30655104
2023 Recombinant PNPLA1 catalyzes the synthesis of acylceramides and acyl acids with selective incorporation of linoleic acid. Journal of lipid research 8 37087101
2019 Novel and Recurrent PNPLA1 Mutations in Spanish Patients with Autosomal Recessive Congenital Ichthyosis; Evidence of a Founder Effect. Acta dermato-venereologica 7 31120544
2018 Prevalence of PNPLA1 Gene Mutation in 48 Breeding Golden Retriever Dogs. Veterinary sciences 7 29738490
2016 Autosomal recessive congenital ichthyosis due to PNPLA1 mutation in a golden retriever-poodle cross-bred dog and the effect of topical therapy. Veterinary dermatology 7 27237723
2021 Variants in the PNPLA1 Gene in Families with Autosomal Recessive Congenital Ichthyosis Reveal Clinical Significance. Molecular syndromology 6 34899144
2017 Identification of two novel PNPLA1 mutations in Turkish families with autosomal recessive congenital ichthyosis. The Turkish journal of pediatrics 6 29624231
2022 PNPLA1-Mediated Acylceramide Biosynthesis and Autosomal Recessive Congenital Ichthyosis. Metabolites 5 35893253
2022 Impaired production of skin barrier lipid acylceramides and abnormal localization of PNPLA1 due to ichthyosis-causing mutations in PNPLA1. Journal of dermatological science 5 35970721
2019 Targeted regions sequencing identified four novel PNPLA1 mutations in two Chinese families with autosomal recessive congenital ichthyosis. Molecular genetics & genomic medicine 5 31833240
2025 Defective targeting of PNPLA1 to lipid droplets causes ichthyosis in ABHD5-syndromic epidermal differentiation disorder. Journal of lipid research 4 40818613
2022 Novel Pathogenic Mutation of PNPLA1 Identified in Autosomal Recessive Congenital Ichthyosis: A Case Report. Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih 3 36647593
2025 Intragenic PNPLA1 duplication in Labrador retrievers with nonepidermolytic ichthyosis. Veterinary dermatology 2 40150930
2025 The First Reported Japanese Case of PNPLA1-Nonsyndromic Epidermal Differentiation Disorder (PNPLA1-nEDD) Associated With an Unreported 92-Base-Pair Duplication Variant. Experimental dermatology 2 40545863
2024 PNPLA1 knockdown inhibits esterification of γ-linolenic acid to ceramide 1 in differentiated keratinocytes. Biochemical and biophysical research communications 2 38340658
2026 Progressive symmetrical erythrokeratoderma associated with biallelic PNPLA1 variants. The British journal of dermatology 1 41530952
2020 [Analysis of PNPLA1 gene mutation in a child with ichthyosis]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 1 32924119
2026 Genome-wide identification of the phospholipase gene family in Panax notoginseng and functional analysis of PnPLA1-8 response to Fusarium oxysporum infection. Plant physiology and biochemistry : PPB 0 41655508
2026 Mutation Analysis in Ten Cases With PNPLA1-Nonsyndromic Epidermal Differentiation Disorder: Evidence of a Founder Effect. The Journal of dermatology 0 41964248

Missed literature

Know a paper Affinage missed for PNPLA1? Flag it for the maintainers and the community.

No submissions yet.